Publication:
Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients

0
0

Issued Date

2012

Resource Type

Article

File Type

application/pdf

ISSN

0264410X

DOI

10.1016/j.vaccine.2011.12.023

Other identifier(s)

2-s2.0-84856314678

Rights Holder(s)

Scopus

Bibliographic Citation

Vaccine. Vol 30, No.6 (2012), p.1108-1114

Suggested Citation

Lertdumrongluk P., Changsirikulchai S., Limkunakul C., Prachukthum P., Punpiput P., Buppanharun R., Chotpitayasunondh C. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. Vaccine. Vol 30, No.6 (2012), p.1108-1114. doi:10.1016/j.vaccine.2011.12.023 Retrieved from: https://hdl.handle.net/20.500.14740/7109

Title

Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients

Author(s)

Lertdumrongluk P.
 Changsirikulchai S.
 Limkunakul C.
 Prachukthum P.
 Punpiput P.
 Buppanharun R.
 Chotpitayasunondh C.

Abstract

A worldwide vaccination campaign against the 2009 pandemic influenza A (H1N1) virus was launched among high-risk subjects, including hemodialysis patients. The long-term immunogenicity of an influenza vaccine has not been investigated in hemodialysis patients. This study aimed to (1) assess the long-term immunogenicity of a monovalent non-adjuvanted influenza A (H1N1) vaccine in hemodialysis patients and (2) determine the safety of this vaccine. We conducted a prospective cohort study of 44 hemodialysis patients and 149 healthy controls in 2010. All of the participants received a single dose of the monovalent non-adjuvanted 2009 influenza A (H1N1) vaccine. The level of antibodies was measured at baseline and at 4 and 24 weeks post-vaccination using a hemagglutination inhibition assay. The outcomes were the percentages of participants who achieved seroconversion and seroprotection (titer ≥1:40) 4 and 24 weeks after vaccination. At 4 weeks post-vaccination, seroconversion was observed in 17 (38.6%) of the hemodialysis patients and 94 (63.1%) of the controls (P= 0.056), and protective titers were obtained in 22 (50%) of the hemodialysis patients and 100 (67.1%) of the controls (P= 0.426). At 24 weeks post-vaccination, immunogenicity decreased in both the hemodialysis patients and the controls, but there were no significant differences between the hemodialysis patients and the controls in the seroconversion rate (27.3% versus 36.9%, P= 0.526) or the seroprotection rate (38.6% versus 48.3%, P= 0.996). No differences in adverse events were observed between the hemodialysis patients and the controls. In summary, the 2009 influenza A (H1N1) vaccine elicits a similar immune response in both hemodialysis patients and healthy controls, but immunity declines 24 weeks after vaccination in both groups. Hemodialysis patients should at least be vaccinated annually against the influenza virus. © 2011 Elsevier Ltd.

Subject(s)

Influenza vaccine
 Virus antibody
 2009 H1N1 influenza
 Adult
 Aged
 Antibody blood level
 Antibody response
 Antibody titer
 Article
 Chill
 Controlled study
 Drug safety
 Female
 Fever
 Headache
 Hemagglutination inhibition
 Hemodialysis patient
 High risk patient
 Human
 Immunogenicity
 Injection site contusion
 Injection site erythema
 Injection site pain
 Injection site swelling
 Major clinical study
 Malaise
 Male
 Myalgia
 Nausea
 Priority journal
 Prospective study
 Rash
 Seroconversion
 Seroprotection
 Treatment outcome
 Virus immunity
 Adult
 Aged
 Antibodies, Viral
 Cohort Studies
 Hemagglutination Inhibition Tests
 Humans
 Influenza A Virus, H1N1 Subtype
 Influenza Vaccines
 Influenza, Human
 Middle Aged
 Prospective Studies
 Renal Dialysis
 Time Factors
 Treatment Outcome

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/7109

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By